The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

By Abern Michael R.   Terris Martha K.   Aronson William J.   Kane Christopher J.   Amling Christopher L.   Cooperberg Matthew R.   Freedland Stephen J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1656-1662

Blackwell Publishing

Access to resources Recommend Favorite

Long-Term Therapy of Venous Thromboembolism in Cancer Patients

By Streiff Michael B.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 9, 2006-10 ,pp. : 903-910

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Degarelix less costly than goserelin for prostate cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 8, 2006-08 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

The possibility of inducing long-term protection against prostate cancer by vaccination may cause a "major paradigm shift"

By  

Inpharma, Vol. 1, Iss. 1633, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite